The effects of guanfacine on working memory performance in patients with localization-related epilepsy and healthy controls

Clinical Neuropharmacology

Volumn 31, Issue 5, 2008, Pages 251-260

  Swartz, Barbara E ^a,e   McDonald, Carrie R ^c   Patel, Ashok ^d   Torgersen, Denise ^b  

^a Hoag Hospital Memorial Presbyterian Epilepsy Center   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e NONE   (United States)

Author keywords

Frontal lobe epilepsy; Working memory

Indexed keywords

GUANFACINE;

ACCURACY; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOCAL EPILEPSY; FRONTAL LOBE; FRONTAL LOBE EPILEPSY; HUMAN; INGESTION; MALE; PRIORITY JOURNAL; SEDATION; TASK PERFORMANCE; TEMPORAL LOBE EPILEPSY; TREATMENT RESPONSE; WORKING MEMORY; ADULT; COMPARATIVE STUDY; MEMORY; METHODOLOGY; MIDDLE AGED; PHOTOSTIMULATION; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOMOTOR PERFORMANCE; REACTION TIME;

ADULT; EPILEPSIES, PARTIAL; EPILEPSY, TEMPORAL LOBE; FEMALE; GUANFACINE; HUMANS; MALE; MEMORY; MIDDLE AGED; PHOTIC STIMULATION; PSYCHOMOTOR PERFORMANCE; REACTION TIME; YOUNG ADULT;

EID: 65849518754     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181633461     Document Type: Article

References (52)

1. Carli M, Robbins TW, Evenden JL, et al. Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav Brain Res 1983;9:361-380.
2. Oke AF, Adams RN. Selective attention dysfunctions in adult rats neonatally treated with 6-hydoxydopamine. Pharmacol Biochem Behav 1978;9:429-432.
3. Tanila H, Rama P, Carlson S. The effects of prefrontal intracortical microinjections of an alpha-2 agonist, alpha-2 antagonist and lidocaine on the delayed alternation performance of aged rats. Brain Res Bull 1996;40:117-119.
4. Leslie FM, Loughlin SE, Sternberg DB, et al. Noradrenergic changes and memory loss in aged mice. Brain Res 1985;359:292-299.
5. Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neurosci 1988;8:4287-4298.
6. Stein L, Belluzzi JD, Wise CD. Memory enhancement by central administration of norepinephrine. Brain Res 1975;84:329-335.
7. McEntee WJ, Mair RG. Memory enhancement in Korsakoff's psychosis by clonidine: further evidence for a noradrenergic deficit. Ann Neurol 1980;7: 466-470.
8. Jakala P, Sirvio J, Riekkinen M, et al. Guanfacine and clonidine, alpha 2-agonists, improve paired associates learning, but not delayed matching to sample, in humans. Neuropsychopharmacology 1999;20:119-130.
9. Bartus RT, Fleming D, Johnson HR. Aging in the rhesus monkey: debilitating effects on short-term memory. J Gerontol 1978;33:858-871.
10. Goldman PS, Rosvold HE. Localization of function within the dorsolateral prefrontal cortex of the rhesus monkey. Exp Neurol 1970;27:291-304.
11. Brozoski TJ, Brown RM, Rosvold HE, et al. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979; 205:929-932.
12. Franowicz JS, Arnsten AF. The alpha-2a noradrenergic agonist, guanfacine, improves delayed response performance in young adult rhesus monkeys. Psychopharmacology (Berl) 1998; 136:8-14.
13. Mishkin M, Manning FJ. Non-spatial memory after selective prefrontal lesions in monkeys. Brain Res 1978;143:313-323.
14. Arnsten AF, Goldman-Rakic PS. Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 1985;230:1273-1276.
15. Sawaguchi T. Attenuation of delay-period activity of monkey prefrontal neurons by an alpha2-adrenergic antagonist during an oculomotor delayed-response task. J Neurophysiol 1998;80:2200-2205.
16. Arnsten AF, Steere JC, Hunt RD. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996;53:448-455.
17. Arnsten A. Catecholamine modulation of prefrontal cortical cognitive function. Trends Cogn Sci 1998;2: 436-446.
18. Jackson WJ, Buccafusco JJ. Clonidine enhances delayed matching-to-sample performance by young and aged monkeys. Pharmacol Biochem Behav 1991;39:79-84.
19. Steere JC, Arnsten AF. The alpha-2A noradrenergic receptor agonist guanfacine improves visual object discrimination reversal performance in aged rhesus monkeys. Behav Neurosci 1997;111:883-891.
20. Li BM, Kubota K. Alpha-2 adrenergic modulation of prefrontal cortical neuronal activity related to a visual discrimination task with GO and NO-GO performances in monkeys. Neurosci Res 1998;31: 83-95.
21. Li BM, Mei ZT. Delayed-response deficit induced by local injection of the alpha 2-adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys. Behav Neural Biol 1994;62: 134-139.
22. Cai JX, Ma YY, Xu L, et al. Reserpine impairs spatial working memory performance in monkeys: reversal by the alpha 2-adrenergic agonist clonidine. Brain Res 1993;614:191-196.
23. Horrigan JP, Barnhill LJ. Guanfacine for treatment of attention-deficit disorder in boys. J Child Adolesc Psychopharmacol 1995;5:215-223.
24. Fields RB, Van Kammen DP, Peters JL, et al. Clonidine improves memory function in schizophrenia independently from change in psychosis. Preliminary findings. Schizophr Res 1988;1:417-423.
25. Mair RG, McEntee WJ. Cognitive enhancement in Korsakoff's psychosis by clonidine: a comparison with l-dopa and ephedrine. Psychopharmacology (Berl) 1986;88:374-380.
26. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34:50-54.
27. Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995;34:1140-1146.
28. Arnsten AF, Goldman-Rakic PS. Analysis of alpha-2 adrenergic agonist effects on the delayed nonmatch-to-sample performance of aged rhesus monkeys. Neurobiol Aging 1990;11:583-590.
29. Witte EA, Marrocco RT. Alteration of brain noradrenergic activity in rhesus monkeys affects the alerting component of covert orienting. Psychopharmacology (Berl) 1997;132:315-323.
30. McGaugh JL, Introini-Collison IB, Nagahara AH. Memory-enhancing effects of posttraining naloxone: involvement of beta-noradrenergic influences in the amygdaloid complex. Brain Res 1988;446: 37-49.
31. Thomas MJ, Moody TD, Makhinson M, et al. Activity-dependent beta-adrenergic modulation of low frequency stimulation induced LTP in the hippocampal CA1 region. Neuron 1996;17: 475-482.
32. Riekkinen M, Riekkinen P Jr. Alpha2-adrenergic agonist clonidine for improving spatial working memory in Parkinson's disease. J Clin Psychopharmacol 1999;19:444-449.
33. Sorkin EM, Heel RC. Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 1986;31:301-336.
34. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2001;21:223-228.
35. 18 FDG-PET study. Neurology 1996;47:1203-1212.
36. 18FDG -PET study of dysfunctional zones. Neurology 1996;46:737-747.
37. 18 FDG-positron emission tomography in normal controls and subjects with epilepsy. Life Sci 1996;58:2057-2064.
38. Krauss GL, Summerfield M, Brandt J, et al. Mesial temporal spikes interfere with working memory. Neurology 1997;49:975-980.
39. Swartz B, Mandelkern A, Torgersen D, et al. Neuromodulatory agents, working memory and focal epilepsy. Epilepsia 1997;88(s3):136.
40. Swartz BE, Kovalik E, Thomas K, et al. The effects of an alpha-2 adrenergic agonist, guanfacine, on rCBF in human cortex in normal controls and subjects with focal epilepsy. Neuropsychopharmacology 2000;23:263-275.
41. 18 FDG-PET study of cortical activation during a short-term visual memory task in humans. Neuroreport 1994;5: 925-928.
42. Swartz B, Halgren E, Fuster J, et al. Cortical metabolic activation in humans during a visual memory task. Cereb Cortex 1995;3:205-214.
43. Braver TS, Barch DM. A theory of cognitive control, aging cognition, and neuromodulation. Neurosci Biobehav Rev 2002;26:809-817.
44. Alvarez JA, Emory E. Executive function and the frontal lobes: a meta-analytic review. Neuropsychol Rev 2006;16:17-42.
45. Coull JT, Frith CD, Dolan RJ, et al. The neural correlates of the noradrenergic modulation of human attention, arousal and learning. Eur J Neurosci 1997;9:589-598.
46. Tsukahara T, Taniguchi T, Usui H, et al. Sympathetic denervation and alpha adrenoceptors in dog cerebral arteries. Naunyn Schmiedebergs Arch Pharmacol 1986;334:436-443.
47. Morrison JH, Molliver ME, Grzanna R. Noradrenergic innervation of cerebral cortex: widespread effects of local cortical lesions. Science 1979;205:313-316.
48. Langer S. Presynaptic receptors and their role in the regulation of transmitter release. Br J Pharmacol 1974;60:481-497.
49. Swartz BE, Halgren E, Ashok TV, et al. "Frontal" neurocognitive tests and regional glucose uptake. Epilepsia 1998;39:247.
50. Swartz BE, Delgado-Escueta AV, Walsh GO, et al. Surgical outcomes in pure frontal lobe epilepsy and foci that mimic them. Epilepsy Res 1998;29: 97-108.
51. MacDonald C, Swartz BE, Halgren E, et al. The relationship of glucose metabolism to executive dysfunction in epilepsy and controls. Epilepsy Behav 2006;9:58-67.
52. Kugler J, Seus R, Krauskopf R, et al. Differences in psychic performance with guanfacine and clonidine in normotensive subjects. Br J Clin Pharmacol 1980;10 suppl 1:71S-80S.